Premium
Effectiveness of GH isoform differential immunoassay for detecting rhGH doping on application of various growth factors
Author(s) -
Okano Masato,
Nishitani Yasunori,
Sato Mitsuhiko,
Kageyama Shinji
Publication year - 2012
Publication title -
drug testing and analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.065
H-Index - 54
eISSN - 1942-7611
pISSN - 1942-7603
DOI - 10.1002/dta.1385
Subject(s) - immunoassay , endocrinology , medicine , gene isoform , growth hormone , hormone , antibody , chemistry , immunology , biochemistry , gene
The analytical method for detecting growth hormone (GH) doping, the so‐called GH isoform differential immunoassay, is currently approved by the World Anti‐Doping Agency (WADA). Anti‐doping laboratories often face challenges by athletes' lawyers and need to have various types of scientific evidence against the claim that the adverse analytical finding (AAF) result was caused by excess ectopic or abnormal excretion. In this work, a population study of Japanese athletes (255 male and 256 female) and administration studies of recombinant human GH (rhGH) in Japanese females were conducted to confirm the applicability of GH isoform differential immunoassay. The present paper describes the effectiveness of the GH isoform differential immunoassay under abnormal excretion of endogenous GH as determined by administration studies of GH releasing hormone (GHRH(1–44)) and insulin‐like growth factor‐1 (IGF‐1). No false positive findings were found in Japanese athletes. The GH isoform differential immunoassays could detect application of rhGH for approximately 12–24 h. The administration of GHRH(1–44) and IGF‐1 as well as ghrelin receptor agonists did not affect the isoform ratio (no false positives). We conclude that the GH isoform differential immunoassay is a highly specific method for detecting rhGH doping. Subject‐based profiling (i.e. athlete biological passport) very likely will represent a highly sensitive approach for detecting rhGH doping. Copyright © 2012 John Wiley & Sons, Ltd.